Case presentation
In 2004, a 19-year-old woman was diagnosed as poorly differentiated adenocarcinoma of the stomach. The carcinoma invaded into the main muscular layer and spread to four lymph nodes, which was classified as stage IIB. Then a total gastrectomy and five cycles of EOF (oxaliplatin + epirubicin + calcium folinate + 5-FU) chemotherapy was conducted. There was no recurrence or metastasis in patient follow-up until 2015 when she presented symptoms of abdominal distension and vomiting. Computer tomography (CT) scan of abdomen and pelvis showed an obstruction in the small intestine. Emergent exploratory surgery revealed a mass located in the middle of intussusception of the ileum, and an excision of the ileum mass was performed. It was thought to be a metastasis of previous gastric adenocarcinoma clinically.
Macroscopically, resected ileum showed a 3×2.7×2 cm 3 mass. The cutting surface was grey-white. Microscopic findings revealed that the tumor was located under the ileum mucosa, arranged in a solid and pseudopapillary pattern ( Figure 1A) . Characteristically, the cells were polygonal in shape, contained clear to eosinophilic cytoplasm and oval nuclei with a single small nucleolus. Scattered osteoclast-like multinucleated giant cells were also identified ( Figure 1B) . Mitotic Figures were found in some fields, but necrosis and ulcer were not extensive. To carefully exclude that the neoplasm was not a metastatic lesion of gastric tumor, we reviewed the slides of the past gastric tumor. The histological and immunohistological findings were quite different. Gastric tumor cells were poorly cohesive with occasional signet-ring cells ( Figure 1C) , and the cells were positive for AE1/AE3 cytokeratin, confirming its epithelial origin. The GNET cells were strongly and diffusely positive for S100 staining, but were negative for AE1/AE3 cytokeratin, A103 and HMB-45 ( Figure 2) . Thus, we considered ileum lesion was a second new neoplasm of different origin in digestive tract compared with previous gastric tumor. To further confirm the results, we conducted fluorescence in situ hybridization (FISH) analysis for
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Figure 2
Immunohistochemistry staining of GNET and gastric tumor. (A) The GNET cells were strongly and diffusely positive for S100
staining, but poorly scattered positive for AE1/AE3 (100×); (B) the GNET cells were negative for A103 and HMB-45 (100×); (C) gastric tumor cells were positive for AE1/AE3, but negative for S100 staining (200×). GNET, gastrointestinal neuroectodermal tumor.
EWSR1 rearrangement. Fifty percent of the cells showed a split signal of EWSR1 in ileum tumor ( Figure 3A) , while in stomach tumor rearrangement of EWSR1 was not detected ( Figure 3B) . One month after surgical resection, the patient received chemotherapy. During the clinical follow-up, the patient kept disease free for 14 mouths. However, she presented a mesentery mass of small intestine in September 2016. Then she received a surgical removal of the mesentery mass. It turned out to be GNET metastasis through pathological examination ( Figure 4A ). After she recovered from surgery, unfortunately, she was found to have mesenteric and lung lesions by the CT scan in January 2018. By conducting percutaneous lung biopsy under the CT, the lesion was confirmed to be a GNET metastasis ( Figure 4B) . The patient was then switched to take sunitinib and still alive till January 2019.
Discussion
Malignant GNET is a rare malignant neoplasm arising in the intestinal tract, stomach, or colon, and occurs predominantly in young adults. Patients usually develop anemia and abdominal pain (5, 6) . CT scan of the abdomen and pelvis helps to detect lesion. GNET is usually associated with high rate of local recurrence, metastasis and its average survival time is 18.5 months (1, 3) . Until now, the etiology of the neoplasm is still unclear and its tumorigenesis is obscure at the initial stages of development.
We reviewed published case reports of GNET, most of which have no history of previous malignancy of any different kind ( Table 1 ). Only two of them were present as a second primary GNET after previously known malignancy. Both patients had been treated with surgery plus low-dose radiotherapy or surgery plus chemotherapy for the previously neoplasm (7-9). One of these patients was diagnosed as hepatoblastoma at age of 13, then he was treated with surgery and followed by six cycles of PLADO regimen chemotherapy (cisplatin and doxorubicin), who eventually developed GNET 20 years later (7) . The same as above, our patient was diagnosed as poorly differentiated adenocarcinoma of stomach 14 years ago, and then received total gastrectomy and five cycles of EOF chemotherapy (oxaliplatin 150 mg 1d + epirubicin 60 mg day 1 + calcium folinate 0.1 g days 1-5 + 5-FU 0.5 g days 1-5). We realized that these two patients underwent similar chemotherapy agents when they were young and developed the same disease eventually, which suggested that chemotherapy might play a role in the tumorigenesis of GNET.
Platinum drugs were conventional chemotherapy drugs for many different solid tumors, including gastric cancer (10) . While doxorubicin was a routine chemotherapy drug in breast cancer, which was rarely administered in gastric cancer in recent years. Actually, combined chemotherapy with platinum and epirubicin was a routine treatment strategy in gastric cancer in early years (11, 12) . Interestingly, the risk of gastric adenocarcinoma increased after chemotherapy of diffuse large B cell lymphoma (13, 14) , and yet secondary malignant tumors after gastric adenocarcinoma chemotherapy were rarely reported. Moreover, there were rare reports showing that platinumbased drugs and doxorubicin, alone or combination, would induce a new neoplasm. Generally, advanced poorly differentiated gastric adenocarcinoma progresses quickly, and five-years overall survival rate is 31%. However, the patient in our case has lived a long life after gastric surgery and chemotherapy. We hypothesized that there might be some unknown germline mutation which played an important role in the natural history of gastric carcinoma in this case, and eventually contributed to the small bowel lesion. Furthermore, germline mutation and prolonged survival made the carcinogenicity of chemotherapy more obvious. Thus, more work should be done to demonstrate if the combination of platinum-based drugs and doxorubicin could contribute to increased possibility of EWSR1 rearrangement, which might cause the onset of GNET. 
